Assyro AI

FDA Orange Book · active-ingredient family

Gadoversetamide

Gadoversetamide is approved in 3 FDA applications, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.

Reference-listed drug:OPTIMARK · NDA 020975

3

Brand (NDA)

0

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · injectable

ProductApplicantApplicationTEApproved
OPTIMARKRLDLIEBEL-FLARSHEIMNDA 020975Dec 08, 1999
OPTIMARKRLD×4LIEBEL-FLARSHEIMNDA 020937Dec 08, 1999
OPTIMARK IN PLASTIC CONTAINERRLD×4LIEBEL-FLARSHEIMNDA 020976Dec 08, 1999

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Gadoversetamide — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.